ReviewBiosensors2026
Progress in (Photo)electrochemical Biosensors for the Detection of Amyloid-Beta Oligomer.
Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) has become a neurodegenerative disease with an increasing incidence rate and a large economic and social burden worldwide. Amyloid-beta oligomer (AβO) has been confirmed as a key neurotoxic species and a core diagnostic biomarker in AD. Traditional methods for AβO detection have drawbacks, such as cumbersome operation, high cost, and dependence on sophisticated instruments, hindering their transformation into fast and real-time detection techniques. (Photo)electrochemical biosensors have attracted much attention due to their inherent advantages, such as high sensitivity, low cost, portability, and ease of miniaturization. This review systematically summarizes the latest progress of (photo)electrochemical biosensors for AβO detection, mainly based on two sensing modes: direct detection and sandwich-type detection. We comprehensively elaborated on the sensing performances and recognition elements, such as antibodies, aptamers, peptides, and molecularly imprinted polymers. The integration of functional nanomaterials and signal amplification strategies was emphasized to improve the sensitivity, selectivity, and stability of biosensors. In addition, we discussed the existing challenges and looked forward to the future development direction for the early diagnosis of AD. This article aims to provide a systematic reference for the rational design and practical application of advanced biosensors in biomarker detection and AD-related precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.